Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL94677 | 1.00 | HCAR2 (0.58) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL94676 | 1.00 | HCAR2 (0.58) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL361271 | 0.85 | HCAR2 (0.59) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL1888855 | 0.85 | HCAR2 (0.59) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL28399684 | 0.85 | HCAR2 (0.52) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL31058784 | 0.82 | HCAR2 (0.46) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL30965305 | 0.82 | HCAR2 (0.46) | HCAR2MAPTNPSR1CA12CA1 | |
| Diethyl Maleate SCHEMBL43033 | 0.82 | HCAR2 (0.80) | HCAR2MAPTNPSR1CA12CA1 | |
| Diethyl Maleate SCHEMBL42602 | 0.82 | HCAR2 (0.80) | HCAR2MAPTNPSR1CA12CA1 | |
| Diethyl Maleate SCHEMBL60423 | 0.82 | HCAR2 (0.80) | HCAR2MAPTNPSR1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059788-B2 | Streamlined syntheses of fluoroquinolones | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2021-07-13 | — | — | US | disclosed |
| US-11059788-B2 | Streamlined syntheses of fluoroquinolones | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200123111-A1 | STREAMLINED SYNTHESES OF FLUOROQUINOLONES | VIRGINIA COMMONWEALTH UNIVERSITY | 2020-04-23 | — | — | US | disclosed |
| US-8987268-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-24 | — | — | US | disclosed |
| US-8921368-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| US-20140011795-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| US-7285686-B2 | Process for the preparation of 1,3-substituted indenes | PFIZER INC (US) | 2007-10-23 | — | — | US | disclosed |
| EP-1537091-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004020420-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011795-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | HCAR2 2881/4885MAPT 4203/4885NPSR1 3563/4885 |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | HCAR2 2884/4885MAPT 4218/4885NPSR1 3477/4885 |
| US-20200123111-A1 | STREAMLINED SYNTHESES OF FLUOROQUINOLONES | NRAS, QARS1, BLM | HCAR2 4582/4885MAPT 3184/4885NPSR1 4694/4885 |
| US-11059788-B2 | Streamlined syntheses of fluoroquinolones | NRAS, QARS1, BLM | HCAR2 4582/4885MAPT 3184/4885NPSR1 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.